Antioxidant therapy in diabetic complications: What is new?

Current Vascular Pharmacology

Volumn 2, Issue 4, 2004, Pages 335-341

  Da Ros, Roberto ^a   Assaloni, Roberta ^a   Ceriello, Antonio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

ACE inhibitors; AT1 receptor inhibitors; Calcium channel blockers; Diabetic complications; Oxidative stress; Statins; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; CELL NUCLEUS RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; TRANSCRIPTION FACTOR;

BIOAVAILABILITY; CELL MEMBRANE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DNA DAMAGE; DRUG MECHANISM; ELECTRON TRANSPORT; ENZYME ACTIVATION; ENZYME INHIBITION; GLYCOLYSIS; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; INTRACELLULAR TRANSPORT; LIPID PEROXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SYMPTOMATOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; DIABETES COMPLICATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS; THIAZOLIDINEDIONES;

EID: 4444265474     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043385538     Document Type: Review

References (107)

1. Kannel WB, McGee DL. Diabetes and cardiovascular diseases. The Framingham Study. JAMA 1979; 241: 2035-2038.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. The Diabetes Control and Complications Trials (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
5. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87: 840-844.
7. Bohlen HG, Lash JM. Topical Hyperglycemia rapidly suppresses EDRF-mediated vasodilatation of normal rat arterioles. Am J Physiol 1993; 265: H219-H225.
8. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-1790.
9. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-154.
10. Tesfamarian B, Coehen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-H326.
11. Ceriello A, Motz E, Giuliano D. Vitamin C and hypertension. Lancet 2000; 355: 1271-1272.
12. Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilatation impaired by acute hyperglycemia in humans. Circulation 2001; 103: 1618-1623.
13. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
14. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
15. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915-918.
16. Baox KJ, Thiel BA, Stuehr DJ. Macrophage nitric oxide synthase subunits. J Biol Chem 1993; 268: 21120-21129.
17. Benz D, Cadet P, Mantione K, Zhu W, Stefano GB. Tonal nitric oxide and health - a free radical and scavenger of free radicals. Med Sci Monit 2002; 8: RA1-4.
18. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28.
19. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-1437.
20. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabò C, et al. Inhibition of GADPH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-1057.
21. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Cimenti S, Medow MS, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensinII-mediated oxidative stress. Diabetes 2001; 50: 1414-1424.
22. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Medicine 2001; 7: 108-113.
23. Marchioli R, Schweiger C, Levantesi G, Gavazzi L, Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 2001; 36: S53-S63.
24. Pacher P, Liaudet L, Garcia Soriano F, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51: 514-521.
25. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-1596.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-1389.
27. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels : the long-term intervention with pravastatin in ischaemic disease (LIPID) Study Group. N Engl J Med 1999; 339: 1349-1357.
28. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Reccurents Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
29. Heart protection study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
30. Ma L, Morita I, and Murota S. Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-Coa reductase inhibitors. Biochem Biophys Res Commun 1994; 203: 135-1361.
31. Schwartz GG, Olsson AG, and Study investigators MIRACL. Effects of atorvastatin on early reccurent ischemic events in acute coronary syndromes. JAMA 2001; 285: 1711-1718.
32. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
33. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707.
34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
35. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347: 102-103.
36. Packard CJ. Influence of pravasnin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
37. Takemoto M, Liao JK. Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzime A Reductase Inhibitors. Atherioscler Thromb Vasc Biol 2001; 21: 1712.
38. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
39. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
40. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11: 2295-2322.
41. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitor. Circulation 1998; 273: 24266-24271.
42. Lauf U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000; 87: 526-528.
43. Laufs U, Liao JK. Direct vascular effects of HMG CoA reductase inhibitors. Trends Cardiovasc Med 2000; 10: 143-148.
44. Bates K, Ruggeroli CE, Goldman S, Gaballa MA. Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 2002; 283: H768-H775.
45. Vidal F, Colome C, Martinez-Gonzales J, Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur J Biochem 1998; 252: 378-384.
46. Everson WV, Smart EJ. Influence of caveolin, cholesterol, andl ipoproteins on nitric oxide synthase: implications for vascular disease. Trend Cardiovasc Med 2001; 11: 246-250.
47. Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective action of statins? Trends Mol Med 2001; 7: 189-191.
48. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905,
49. Vecchione C, Brandes RP. Withdrawal of the 3-hydroxy-3-methylglutaryl coenzime A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Cire Res 2002; 91: 173-179.
50. Dusi S, Domini M, Rossi F. Mechanism of NADPH oxidase activation in human neutrophils: p67phoxis required for translocationof rac1 but not rac2 from cytosol to the membranes. Biochem J 1995; 308: 991-994.
51. Wassmann, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vase Biol 2002; 22: 300-5.
52. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-Hydroxy-3-Methylglutaryl Coenzime A Reductase Inhibitors, atorvastatin and simvastatin, on the expression of the endothelin-1 and endothelial nitric oxide synthase in vascular endothelial ells. J Clin Invest 1998; 101: 2711-2719.
53. TH Achmad, GS Rao. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blokers, Biochem Biophys Res Commun 1992; 189: 994-1000.
54. McCarron RM, Wang L, Stanimirovic DB, Spatz M. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett 1993; 156: 31-34.
55. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Buis B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218.
56. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 2004; 53: 701.
57. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003; 289: 16756-1680.
58. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.
59. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
60. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part 1: oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
61. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol 2001; 281: R795-R802.
62. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
63. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-2183.
64. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotnesin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT-1-receptor expression an rac1 GTPase. Mol Pharmacol 2001; 59: 646-654.
65. Wang W, Wang S, Yan L, Madara P, Del Pilar Cintron A, Wesley RA, et al. Superoxide production and reactive oxygen species signaling by endothelial nitric-oxide synthase. J Biol Chem 2000; 275: 16899-16903.
66. Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87: 566-573.
67. Hornig B, Landmesser U, Kohler C. Comparative effect of ACE inhibition AND Angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. Circulation 2001; 103: 799-805.
68. Munzel T, Keaney JF. Are ACE inhibitors a "Magic Bullet" against oxidative stress? Circulation 2001; 104: 1571-4.
69. Ceriello A, Motz E. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002; 346: 705-707(letter).
70. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
71. No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
72. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
73. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
74. de Cavanagh E, Inserra F, Tobli J, Stella I, Fraga CG, Ferder L. Enalapril attenuate oxidative stress in diabetic rats. Hypertension 2001; 38: 1130-6.
75. de Cavanagh E, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathione- dependent antioxidant defenses in mouse tissue. Am J Physiol 2000; 278: R572-R577.
76. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent reglation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type I receptor blockade in patients with coronary artery - disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-51.
77. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
78. Wassman S, Hilgers S, Laufs U, Bohm M, Nickenig. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208-1212.
79. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progrenion of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102(13): 1503-10.
80. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106(19): 2422-7.
81. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23(12): 2155-63.
82. Mak IT, Kramer JH, Weglicki WB. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells, and perfused rat hearts. Coron Artery Dis 1992; 3: 1095-1103.
83. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30(2): 569-75.
84. Stumvoll M, Haring H-U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-22.
85. Kliewer SA, Forman BM, Blumberg B, Ong EG, Borgmeyer U, Mangeldorf DJ et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-7359.
86. Lemberg T, Desvergne B, Wahli W. PPARs, a nuclear receptor signaling pathway in lipid metabolism. Annu Rev Cell Dev Biol 1996; 12: 335-363.
87. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
88. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 395: 7614-7619.
89. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
90. Jiang C, Ting AT, Seed B. PPARγ agonist inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
91. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 2000; 101: 235-238.
92. Da Ros R, Assaloni R, Ceriello A. The preventive antioxidant action of thiazolinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med, in press
93. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Molecular and Cellular Biology 2000; 20: 4699-4707.
94. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-γ agonists. The Journal of Immunology 2000; 164: 1498-1504.
95. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol 2001; 98: 337-45.
96. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. The Journal of Neuroscience 2000; 20: 6862-6867.
97. Tsuji, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decrease collagen accumulation in prediabetic stage of type 2 diabetic rat. J Cardiovasc Pharmacol 2001; 38: 868-874.
98. Tsuji, Mizushige K, Noma T, et al. Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in prediabetic stage of Otsuko Long-Evans Tokushima fatty rats. Cardiovasc Drugs Ther 2002; 16: 429-434.
99. Bagi Z, Koller A, Kaley G. Peroxisome proliferator-activated receptor-gamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles in type 2 diabetes. Am J Physiol 2004; 286: H742-H748.
100. Wayman NS, Hattori Y, Mcdonald M, Mota-Filipe H, Cuzzocrea S, Pisano B et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α.) reduce myocardial infarct size. FASEB J 2002; 16: 1027-1040.
101. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805-2811.
102. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1995; 45: 1168-1173.
103. Zhu P, Lu P, Xu P, Schartz GC. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-1171.
104. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-1514.
105. Yin T, Sandhu G, Wolfrang CD, Burrier A, Webb RL, Rigel DF, et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem 1997; 272: 19943-19950.
106. Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000; 49: 2170-2177.
107. Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG. The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes 2003; 52: 846-851